Page 1

TACCIT • transgene 2026 Half - Year Results and Business Update PRESS RELEASE Transgene Extends its myvacⓇ Platform , Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field GTA myvac® - Expanding potential across solid tumors through viral vector , Al driven neoantigen selection , and scalable cell - line manufacturing TG4050 - First Individualized Neoantigen Therapeutic Vaccine ( INTV ) from the myvacⓇ platform advancing in resected HNSCC1 Randomized Phase 1 data published in Nature Communications ; Sustained 100 % disease - free survival ( DFS ) after more than 3 years of follow - up , showing durable clinical outcomes and potential to prevent cancer recurrence Randomized Phase 2 recruitment completed , trial is ongoing with topline results expected in Q1 2028 Preparing for potential pivotal trial in HNSCC with cell - line manufacturing TG4070 - Second novel myvacⓇ - based INTV in early - stage NSCLC² , with potential to be applied across multiple early - stage solid tumor types Leverages Transgene's proprietary Al driven neoantigen selection ( SNIPER ™ ) and cell - line manufacturing All clinical sites open for randomized Phase 1 trial Positive preclinical data from TG - MVA ™ , a new generation of prophylactic vaccine against mpox and smallpox based on MVA vector STACCT IN Business funded until early 2028 Strasbourg , France , September 24 , 2026 , 5:45 pm CET - Transgene ( Euronext Paris : TNG ) , a biotech company developing myvacⓇ , an individualized neoantigen therapeutic vaccines ( INTV ) platform designed to prevent cancer recurrence and a portfolio of virus - based candidates , today publishes its financial results for the six months ended June 30 , 2026 , and provides an update on the progress of its pipeline and its upcoming plans . AAA @ CONT 1 HNSCC : Head and Neck Squamous Cell Carcinoma 2 NSCLC : Non - Small Cell Lung Cancer 1 0000